RIO DE JANEIRO, BRAZIL - A study conducted in Hong Kong found that individuals vaccinated with Pfizer-BioNTech's coronavirus immunizer have 10 times more antibodies than those vaccinated with Sinovac, and that the latter produce "similar or lower" levels of virus-targeting proteins than naturally produced in recovered Covid-19 patients.
The University of Hong Kong findings, published Friday in the scientific journal Lancet Microbe, may suggest the need for "alternative strategies" - including booster vaccines - to enhance antibody levels in Sinovac-immunized individuals and protection against Covid-19 disease, according to the researchers.
The presence of antibodies is an indication . . .